Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.930 +0.180 (+10.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Leadership Changes
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the AACR Annual Meeting 2023
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Upcoming Investor Conferences
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
News headline image
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the SITC 37th Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.